SS&H Financial Advisors Inc. Sells 6,117 Shares of Pfizer Inc. (NYSE:PFE)

SS&H Financial Advisors Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.8% during the second quarter, Holdings Channel reports. The fund owned 72,573 shares of the biopharmaceutical company’s stock after selling 6,117 shares during the period. SS&H Financial Advisors Inc.’s holdings in Pfizer were worth $2,031,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer in the 2nd quarter worth approximately $29,000. Quarry LP bought a new position in Pfizer in the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer during the 4th quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its position in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE stock opened at $28.67 on Wednesday. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market cap of $162.46 billion, a PE ratio of -477.83, a P/E/G ratio of 1.27 and a beta of 0.68. The business’s 50-day moving average price is $29.28 and its two-hundred day moving average price is $28.31.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the firm earned $0.67 EPS. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on PFE shares. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, September 16th. Finally, StockNews.com lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.